Skip to content
Lower risk Drug recall · FDA · Published March 17, 2022

Aurolife Glycopyrrolate Tablets Recall: Glass Pieces Found in Sealed Bottles

Aurolife Pharma recalls 1 mg Glycopyrrolate tablets due to glass fragments in sealed bottles. This risk requires immediate action to avoid potential injury.

🇺🇸 FDA recall #D-0736-2022DrugAurolife ›
Take action

Contact the company

Recalling firmAurolife Pharma, LLC2400 US Highway 130 · Dayton, NJ 08810-1519
✎ GovInfoNow plain-language explainer

Aurolife Pharma is recalling 100-count bottles of 1 mg Glycopyrrolate tablets after complaints about glass pieces found in sealed bottles. This could cause injury if the tablets are swallowed or ingested. Read more at govinfonow.com/recall/35074-aurolife-glycopyrrolate-tablets-recall-glass-pieces-found-in-sealed-bottles.

Source Summary by GovInfoNow · govinfonow.com/recall/35074-aurolife-glycopyrrolate-tablets-recall-glass-pieces-found-in-sealed-bottles · Updated August 18, 2026 · FDA enforcement record: FDA #D-0736-2022

Cite this page

“Aurolife Glycopyrrolate Tablets Recall: Glass Pieces Found in Sealed Bottles.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35074-aurolife-glycopyrrolate-tablets-recall-glass-pieces-found-in-sealed-bottles. Based on FDA recall #D-0736-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0736-2022%22&limit=1).

The FDA announced on March 17, 2022, that Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg due to the presence of glass fragments. The agency classified the recall as Class II.

How to tell if you have it

  • Brand: Aurolife
  • Product: Glycopyrrolate Tablets, USP, 1 mg, 100-count bottle
  • NDC: 13107-014-01
  • Lot code: 01421008A1
  • Expiration date: 03/2023
  • Distribution: Nationwide in the USA and Puerto Rico

The hazard

The recall addresses complaints of pieces of glass discovered in a sealed bottle, which originated from equipment within the packaging room. The FDA stated this foreign substance poses a risk to consumers.

Context

GovInfoNow's records show Aurolife Pharma, LLC has issued three other recalls since August 23, 2019. Recent similar recalls include an Aurolife Glycopyrrolate Tablets recall on May 18, 2023, and another on December 16, 2022, both citing failed impurities or degradation specifications. Other recent recalls of similar products include Guardian Drug CAREone Calcium Antacid Recall (May 28, 2026), Guardian HyVee Antacid Tablets Recall (May 28, 2026), and Guardian Drug recalls EQUALINE antacid tablets with metal particles (May 28, 2026).

How to tell if you have this one

Check for the 100-count bottle labeled 'Glycopyrrolate Tablets, USP, 1 mg' with NDC 13107-014-01. The lot number 01421008A1 was produced for this recall.

  • Brand
    Aurolife
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check for Glass Fragments

    Inspect the bottle for any glass pieces before use. If found, stop using the tablets immediately.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2 years after the firm started it.

1. Firm started the recall: Mar 17, 202212. FDA classified it Class II: Mar 30, 202223. Published in FDA’s Enforcement Report: Apr 6, 202234. FDA terminated the recall: Mar 25, 2024420222024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0736-2022 (March 17, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0736-2022 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA